Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Sell Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Cipla as the stock may fall further.

    • Buy Cipla, advises Sushil Kedia

      Sushil Kedia of Dir-Quantitative Strategy, CIMB recommends buying Cipla within the pharma space. "One may see Hindustan Unilever rebounding by 10-15 percent from the current levels," he adds.

    • Cipla may bounce back, says Ambareesh Baliga

      Ambareesh Baliga of Edelweiss Financial Services is of the view that Cipla may bounce back over the next few weeks.

    • Buy Cipla at around Rs 370-390: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Cipla at around Rs 370-390 with a two year time frame.

    • Expect Cipla to touch Rs 360-370: Pankaj Jain

      Pankaj Jain of Sunteck Wealthmax is of the view that Cipla may touch Rs 360-370. "The company is expected to grow at about 15 percent plus on compounding basis," he adds.

    • Buy Sun Pharma, Cipla: Gopi Suvanam

      According to Gopi Suvanam, Founder of InvestWorks, one may buy Cipla and Sun Pharmaceutical Industries in the pharma space.

    • Super Six: Top chart picks for October 24

      Shrikant Chauhan of Kotak Securities advises buying United Spirits with a target of Rs 2850-2900 and Bank of Baroda with a target of Rs 625.

    • Buy Cipla, Hero Motocorp, says Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Cipla and Hero Motocorp.

    • Buy Tata Elxsi, Cipla; sell LIC Housing Fin: D Cunha

      Lancelot D Cunha of ITI Wealth Management recommends buying Tata Elxsi with a target of Rs 195.80 and advises selling LIC Housing Finance with a target of Rs 193.50.

    • Bull's Eye: Buy Voltas, Cipla; short LIC Housing Fin, BHEL

      Saurabh Mittal of Swadeshi Credits advises buying Voltas with a target price of Rs 78 and Dishman Pharma with a target price of Rs 52.

    • Pick Cipla, advises Gopi Suvanam

      According to Gopi Suvanam of Investworks, one may pick Cipla.

    • Buy Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla as the stock may head higher.

    • Expect Cipla to touch Rs 462, says Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker is of the view that Cipla may touch Rs 462 in the next four-five trading sessions.

    • Buy Sun Pharma, Cipla, Dr Reddys Labs: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, pharma stocks look attractive and advises buying Sun Pharmaceutical Industries, Cipla and Dr Reddys Laboratories.

    • Buy Cipla, Lupin, Sun Pharma for long term: Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may buy Cipla, Lupin, Sun Pharmaceutical and Dr Reddys Laboratories at current level with a long term view.

    • Buy Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla as the stock may move up by another 10 percent.

    • Buy Cipla 440 Call, advises VK Sharma

      According to VK Sharma of HDFC Securities, one may buy Cipla 440 Call at around Rs 13 with a stoploss at Rs 9.

    • Prefer Lupin, Sun Pharma, Cipla: Nischal Maheshwari

      Nischal Maheshwari of Edelweiss Financial Services advises to prefer Lupin, Sun Pharmaceutical Industries and Cipla from pharma space.

    • Cipla may touch Rs 455-460, says SP Tulsian

      According to SP Tulsian of sptulsian.com, one can expect an upside of 30 percent in Cipla at Rs 455-460 as the company has been consistently posting good numbers.

    • Super Six stocks you can bet on September 10

      Pritesh Mehta of IIFL suggests buying Siemens with a target of Rs 490 and HDFC with a target of Rs 810.

    • Buy HDFC, Cipla, Aurobindo Pharma: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers recommends going long on HDFC with a target of Rs 810 and Cipla with a target of Rs 450-455. "One may also go long on Aurobindo Pharma with a target of Rs 210 in the next three-five trading sessions," he adds.

    • Buy Lupin, Cipla & Dr Reddys Labs: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Lupin, Cipla and Dr Reddys Laboratories.

    • Super Six stocks you can bet on September 04

      Rakesh Gandhi of FRR Shares suggests selling Punjab National Bank with a target of Rs 375 and buying Tech Mahindra with a target of Rs 1475.

    • Super Six buy/sell call for September 02

      Aditya Agarwal of Way2Wealth Securities suggests buying Bharti Airtel with a target of Rs 320 and Arvind with a target of Rs 84.

    • Super Six buy/sell calls for August 23

      Rajesh Jain of Religare Securities sugests buying NMDC with a target of Rs 124 and Cipla with a target of Rs 410.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347